Stage
No active trials
Next date
None yet
Trials
0 active
5 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients \> 45 kg/99 lbs: idebenone 2250 mg/day”In the company’s words, NCT00537680 on ClinicalTrials.gov
- Tested for
- Friedreich's Ataxia (2 trials), Leber's Hereditary Optic Neuropathy (LHON), Duchenne Muscular Dystrophy, Duchenne Muscular Dystrophy (DMD)
- Main trialPhase 4
- “LEROS is an open-label interventional Phase IV study, designed to further assess the efficacy and safety of Raxone® in the long-term treatment of LHON patients.”In the company’s words, NCT02774005 on ClinicalTrials.gov
- Other names
- Raxone
Other drugs for Friedreich's Ataxia
- NomlabofuspLarimar Therapeutics, Inc. · Phase 3
- OmaveloxoloneBiogen · Phase 3
- VatiquinonePTC Therapeutics · Phase 3
- DT-216P2Design Therapeutics, Inc. · Phase 1/2
- GV101Graviton Bioscience Corporation · Phase 2
- ATI-105Adjuvia Therapeutics, Inc. · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Completed | 29 Mar 2021 | Study to Assess the Efficacy and Safety of Raxone in LHON Patients | |
| Phase 3Completed | Apr 2009 | Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia | |
| Phase 3Completed | May 2010 | Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients | |
| Phase 3Terminated | 25 Nov 2020 | Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E) | |
| Phase 3Terminated | 1 Dec 2020 | A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026